

## Special Issue

# Combating Antifungal-Resistant and -Tolerant Fungi in the Clinic

### Message from the Guest Editors

Dear colleagues, The emergence of drug-resistant and multidrug-resistant (MDR) fungi combined with the limited antifungal armamentarium poses a serious threat to contemporary medicine for the management of invasive infections caused by fungi. Therefore, in this current issue, we aim at highlighting the burden of invasive fungal infections in humans and how drug-resistant and -tolerant fungi have complicated management of IFIs caused by such species. We encourage papers with a major focus on:

- Mechanisms underlying antifungal resistance and tolerance
- New antifungal agents
- The application of antifungal stewardship in clinic and its association with the burden of drug-resistant fungi
- New methods to improve the current antifungal susceptibility and tolerance testing protocols to rapidly identify drug-resistant/ tolerant fungi

Moreover, review papers describing the burden of drug resistance and the underlying mechanisms in emerging fungal species are welcome and we encourage reaching out to . Keywords: antifungal resistance; antifungal tolerance; identification of antifungal resistance and tolerance; new antifungal agents; antifungal stewardship

---

### Guest Editors

Prof. Dr. Cornelia Lass-Flörl

Dr. Amir Arastehfar

Dr. Erika Shor

---

### Deadline for manuscript submissions

closed (31 December 2021)



## Antibiotics

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.6  
CiteScore 8.7  
Indexed in PubMed



[mdpi.com/si/71408](https://mdpi.com/si/71408)

*Antibiotics*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[antibiotics@mdpi.com](mailto:antibiotics@mdpi.com)

[mdpi.com/journal/  
antibiotics](https://mdpi.com/journal/antibiotics)





# Antibiotics

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.6  
CiteScore 8.7  
Indexed in PubMed



[mdpi.com/journal/  
antibiotics](https://mdpi.com/journal/antibiotics)



## About the Journal

### Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

---

### Editor-in-Chief

Prof. Dr. Nicholas Dixon  
School of Chemistry and Molecular Bioscience, University of  
Wollongong, Wollongong, NSW 2522, Australia

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)